Logo Image
|Articles|September 8, 2003

Intradigm Corporation Announces Development of siRNA Inhibitors of SARS coronavirus

ROCKVILLE, Md. -- Intradigm Corporation, a leader in RNAi application in vivo, has obtained results showing that newly developed siRNA agents selective for specific SARS viral genes can inhibit viral infection and replication in cell based studies showing up to 90 percent inhibition of the virus. The results were obtained from a collaboration that includes Qiagen and Top Biotech, Ltd (Hong Kong).

In the studies performed, a large number of siRNA agents directed toward genes throughout the SARS coronavirus genome were designed by Qiagen and Intradigm, synthesized by Qiagen, and tested in non-human primate cells exposed to SARS virus. The results reveal which SARS viral sequences provide the best targets for inhibition of viral infection and replication and in addition, strong synergistic effects of inhibiting several targets simultaneously. The results provide strong evidence that the siRNA agents developed are specific and potent agents for inhibition of SARS coronavirus.

Intradigm has developed systemic and local siRNA delivery technologies for knocking down disease genes in animals and has validated in in-vivo models the therapeutic potentials of siRNA agents for treatment of cancer, viral infection and other unmet clinical needs. Using effective airway delivery of siRNA duplexes specific to SARS coronavirus, a single stranded RNA virus, may represent a novel approach to treat the deadly infection. Intradigm has established collaboration for development of siRNA based anti-SARS therapy with scientists in National Institute of Allergy and Infectious Diseases (NIAID) of the United States and in Hong Kong and Guangzhou of China.

John Spears, chairman and CEO of Intradigm said, "We are very excited to see this result, which is further evidence that the utilization of siRNA may potentially enable rapid identification and development of anti-viral therapeutics. We are looking forward to working with Qiagen and our other partners for further development of siRNA based therapeutics."

The in-vitro studies were conducted in laboratories in Hong Kong and Guangzhou, China, sponsored by Guangdong provincial government and Top Biotech, Ltd (Hong Kong) where the scientific teams, led by professors Nanshan Zhong, Baojian Li and Bojian Zheng, are composed of scientists from Guangzhou Medical University, Zhongshan University, Hong Kong University and Top Biotech, Ltd. Intradigm's scientific team has worked closely with these Chinese collaborators.

Intradigm Corporation is a privately held Delaware corporation that is discovering and developing therapeutic products by applying proprietary in vivo RNAi delivery technologies.

Source: Intradigm Corporation

Related to this article

View more
Infection preventionists in full PPE with children in DRC. (Image credit: author with AI)
Chasing the Bundibugyo Outbreak: How Static Numbers Hide a Moving Epidemic
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Read more
Health care workers from the US speaking with other health care workers in DRC. (Image credit: author with AI)
What Outbreak Metrics Can and Cannot Tell Us About the Ebola DRC Response
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.
Read more
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange26: Building Safer, Smarter Reusable Linen Programs
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
Read more
A group of students raising their hands in class during a lecture (Adobe Stock 292282454 by Mediteraneo
Once a Teacher, Always a Teacher: Why Infection Prevention Is Education
How do you celebrate an infection that never happened? That's one of the unusual challenges infection preventionists share with teachers. Both can spend their careers changing outcomes they may never see. Both educate people who don't always want to listen. Both are second-guessed. Both face burnout. And both must somehow keep remembering why they started.
Read more